Apollon Wealth Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Apollon Wealth Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.12M	Buy	+123,449	New	+$3.07M	0.05%	306

Other funds holding RARE

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Apollon Wealth Management's RARE Position: Q2 2026 in Review

Apollon Wealth Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 123,449 shares worth $4.12M. The stake represents 0.05% of the portfolio and ranks #306 among its holdings.

36 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Apollon Wealth Management held 123,449 shares of Ultragenyx Pharmaceutical worth $4.12M as of Q2 2026.
Ultragenyx Pharmaceutical was a new Apollon Wealth Management position in Q2 2026.
Ultragenyx Pharmaceutical made up 0.05% of Apollon Wealth Management's portfolio in Q2 2026, its #306 holding.
36 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.